Methylene Blue Treatment of Chronic Hepatitis B Virus Infection

Plain-language guide to NCT06887036: phase 2 interventional trial of Methylene blue (non-peptide stack partner), 10 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06887036
Phase: phase 2
Status: recruiting participants
Start: 2025-09-01
Completion (planned or actual): 2027-05-31
Participants: 10 (estimated)
Design: na, open label (everyone knows who gets what), treatment
Conditions studied: Chronic HBV Infection
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered phase 2 trial tested Methylene blue (non-peptide stack partner).

HBV infection is a global public health problem.

Diagnosis and treatment depend on the stage of infection, the degree of liver inflammation, and the progression of fibrosis.

It had 1 arm (groups): Methylene Blue (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 10 planned participants were the target.

It was open to people of any sex aged from 18 years up to 79 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Signed informed consent. Age ≥ 18 and \< 80 years. Microbiologically confirmed chronic Hepatitis B Virus infection (according to the old terminology "inactive HBV carrier"). Negative pregnancy test in women of child-bearing age.

The full record lists 6 inclusion and 10 exclusion criteria; among the exclusions: documented refusal to participate in the study; known g-6-phophatase deficiency; treatment with a serotoninergic drug.

How the Study Was Run

Design: single-group and open-label.

Everyone knew when Methylene blue (non-peptide stack partner) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-09-01 with completion listed for 2027-05-31.

It ran at 1 site in Switzerland.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 2 secondary outcomes, for example Adverse Events and Treatment adherence.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Methylene blue (non-peptide stack partner) in 10 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.

Our Notes on the Compound

Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.

Methylene blue (non-peptide stack partner) in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.